A next-generation Biotechnology company creating off-the-shelf cellular medicines for Cancer, Infectious Diseases, and Degenerative Diseases.
GX Acquisition Corp has entered into a definitive agreement with Celularity.
News from Celularity:
Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products
Read More Natalin and Acelagraft are the latest additions to Celularity’s portfolio of HCT/P 361 products for use in the treatment of partial and full thickness acute and chronic wounds FLORHAM PARK, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced that on…
Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company
Read More Leverages Celularity World-class Manufacturing Capabilities FLORHAM PARK, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that it has entered into a Master Services Collaboration Agreement with BlueSphere Bio, Inc. (BSB) covering manufacturing activities for certain BSB cell therapy…
MASS Coalition Welcomes Trump Order Freezing Skin Substitute LCDs
Read More FLORHAM PARK, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) — Celularity issues the following announcement on behalf of the members of the MASS Coalition: MASS Coalition Welcomes Trump Order Freezing Skin Substitute LCDs President Trump’s Freeze Order Applies to Skin Substitute LCDs – LCDs will not be effective until at least April 13, 2025 The…
Continue Reading MASS Coalition Welcomes Trump Order Freezing Skin Substitute LCDs
Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023
Read More Celularity filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024, and is now current with its quarterly report filings Reported Total Net Revenue for the Three Months and the Nine Months ending September 30, 2024, are consistent with last guidance, with significant growth over the same periods in 2023…
Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million
Read More Celularity Raises Full Year 2024 Expected Net Sales Guidance to $54 Million to $60 Million, Compared to Previous Guidance of $50 Million to $56 Million October Expected Net Sales of $8.3 Million to $8.9 Million Marks the Highest Single-Month Figure in its History Celularity Filed its Second Quarter Form 10-Q and is Now…
Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel
Read More FLORHAM PARK, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, today announced that it has requested a hearing before the Nasdaq Hearings Panel (the “Hearings Panel”) the Nasdaq Listing Qualifications Department’s determination regarding Celularity’s non-compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”) and…
[fts_twitter twitter_name=celularity tweets_count=6 cover_photo=no stats_bar=no show_retweets=no show_replies=no]